GlassScriptPhysician profile
Anna Grace Snyder
NPI 1265944763
$7,377.97
in general payments reported to CMS, 2019-2025
31 companies · $19.64 in 2025
The $19.64 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $532 · 2022: $2,269 · 2023: $2,636 · 2024: $1,922 · 2025: $19.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,576.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,529.87 | 2021-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,143.32 | 2021-2024 | |
| Genzyme Corporation | $514.82 | 2022-2024 | |
| Janssen Biotech, INC. | $509.62 | 2021-2024 | Stelara, Tremfya, Simponi |
| Ardelyx, INC. | $442.52 | 2022-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $407.12 | 2022-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $375.28 | 2022-2024 | Entyvio, Gattex |
| Intercept Pharmaceuticals, INC. | $227.42 | 2021-2024 | |
| Nestle Healthcare Nutrition INC. | $226.64 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $198.86 | 2021-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $190.93 | 2021-2024 | Linzess |
| Qol Medical, LLC | $187.40 | 2022-2024 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $162.40 | 2022-2023 | Clenpiq, Rebyota |
| Pfizer INC. | $152.08 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $136.44 | 2021-2024 | Givlaari |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $135.61 | 2022-2024 | Zeposia |
| Amgen INC. | $123.18 | 2022-2023 | Amjevita |
| Phathom Pharmaceuticals, INC. | $97.34 | 2023-2024 | Voquezna |
| Aimmune Therapeutics, INC. | $95.14 | 2024 | |
| Gilead Sciences, INC. | $93.24 | 2021-2024 | |
| Braintree Laboratories, INC. | $84.87 | 2021-2023 | Suflave |
| Lilly USA, LLC | $73.77 | 2024 | Omvoh |
| Intra-Sana Laboratories | $56.40 | 2022 | |
| Shield Therapeutics INC | $36.43 | 2024 | |
| Fresenius Kabi USA, LLC | $35.67 | 2023-2024 | Idacio |
| Celltrion USA INC. | $35.66 | 2024 | Vegzelma |
| Boston Scientific Corporation | $28.76 | 2021 | |
| Madrigal Pharmaceuticals | $22.54 | 2024 | Resmetirom |
| Hologic Sales and Service, LLC | $21.44 | 2023 | Fluent Fluid Management System |
| W. L. Gore & Associates, INC. | $19.00 | 2022 | |
| Evoke Pharma, INC. | $14.20 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.